Why carry out this study?
|
There are a limited number of QT studies of intravenous drugs administered over 3 h in duration. |
Daratumumab, a monoclonal antibody administered intravenously, is used to treat multiple myeloma; it targets CD38, a 45-kD transmembrane glycoprotein that is highly expressed on myeloma cells. |
CD38 is also expressed on cardiomyocytes, and daratumumab therapy may have an effect on patient cardiac function; therefore, a QTc substudy was conducted using patients from the phase 2 CENTAURUS study, which evaluated daratumumab 16 mg/kg administered intravenously in patients with intermediate- or high-risk smoldering multiple myeloma. |
What was learned from the study?
|
Primary time-matched time-point and pharmacokinetic-pharmacodynamic analyses showed a small but clinically insignificant effect of daratumumab monotherapy on QTc in patients with intermediate- or high-risk smoldering multiple myeloma, which was confirmed in pre-specified sensitivity analyses. |
The small increase in QTcF observed in this substudy was of similar magnitude to that reported for many other approved oncologic therapies. |
Digital Features
Introduction
Methods
Study Design
Patients
Endpoints and Assessments
Statistical Analysis
Results
Patients
All patients pooled (N = 31) | |
---|---|
Median (range) age, years | 64.0 (39–77) |
Female, n (%) | 19 (61.3) |
Race, n (%) | |
White | 29 (93.5) |
Black or African American | 1 (3.2) |
Asian | 1 (3.2) |
Median (range) weight, kg | 75.00 (50.0–115.3) |
ECOG performance status score, n (%) | |
0 | 28 (90.3) |
1 | 3 (9.7) |
Time-Point Analyses
Outlier Analyses
All patients pooled (N = 31) | |
---|---|
Heart rate outliers, n (%) | |
Tachycardic | 1 (3) |
Bradycardic | 0 |
PR interval outliers, n (%) | 0 |
QRS interval outliers, n (%) | 0 |
QT interval outliers, n (%) | |
New > 500 ms | 0 |
QTcF outliers, n (%) | |
New > 500 ms | 0 |
New > 480 ms | 0 |
> 30–60 ms increase | 2 (6) |
> 60 ms increase | 0 |
Morphology, n (%) | |
New atrial fibrillation | 0 |
New atrial flutter | 0 |
New abnormal U waves | 0 |
New ST segment depression changes | 1 (3) |
New ST segment elevation changes | 0 |
New T wave inverted | 0 |
New second-degree heart block | 0 |
New third-degree heart block | 0 |
New complete right bundle branch block | 0 |
New complete left bundle branch block | 0 |
New myocardial infarction | 0 |
Morphological Analyses
Pharmacokinetic-Pharmacodynamic Analyses
Sensitivity Analyses
Mean change from baseline | All patients pooled (N = 31) |
---|---|
Heart rate, bpm | 10.0 |
PR interval, ms | −6.6 |
QRS interval, ms | −1.7 |
QTcF, ms | 1.9 |